AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD

Grant

Awarded By

Total Award Amount

  • 21200.00

    • Direct Costs

  • 16825.00

    • Sponsor Award Id

    • Contributor

  • Christina Bemrich-Stolz   Investigator  
  • Gregory Friedman M.D.   Investigator  
  • Jeffrey Lebensburger   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Lee Hilliard   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Thomas Howard   Investigator